These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26748629)

  • 1. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial.
    Satoi S; Sho M; Yanagimoto H; Yamamoto T; Akahori T; Kinoshita S; Nagai M; Hirooka S; Yamaki S; Nishiwada S; Ryota H; Ikeda N; Nakajima Y; Kon M
    J Hepatobiliary Pancreat Sci; 2016 Mar; 23(3):167-73. PubMed ID: 26748629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Nagai M; Sho M; Satoi S; Toyokawa H; Akahori T; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kinoshita S; Nishiwada S; Ikeda N; Kwon AH; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2014 Mar; 21(3):186-92. PubMed ID: 23798362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancrelipase with branched-chain amino acids for preventing nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Yamazaki S; Takayama T; Higaki T; Moriguchi M; Yoshida N; Miyazaki T; Teshima Y
    J Gastroenterol; 2016 Jan; 51(1):55-62. PubMed ID: 25904096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
    Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
    Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
    Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
    Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease after pancreatoduodenectomy is closely associated with postoperative pancreatic exocrine insufficiency.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sasaki H; Okano K; Sueda T
    J Surg Oncol; 2014 Nov; 110(6):720-6. PubMed ID: 24965234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial.
    Yasukawa K; Shimizu A; Yokoyama T; Kubota K; Notake T; Seki H; Kobayashi A; Soejima Y
    J Am Coll Surg; 2020 Dec; 231(6):658-669. PubMed ID: 32927075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
    Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
    Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer.
    Saito T; Nakai Y; Isayama H; Hirano K; Ishigaki K; Hakuta R; Takeda T; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Takahara N; Hamada T; Uchino R; Mizuno S; Mouri D; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Yamamoto N; Tada M; Koike K
    Pancreas; 2018 Aug; 47(7):800-806. PubMed ID: 29851751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are minimicrosphere pancrelipase capsules effective enough for the treatment of pancreatic steatorrhea?
    Chung JP; Lee SJ; Park HJ; Lee KS; Chung JB; Lee SI; Kang JK
    Am J Gastroenterol; 2001 May; 96(5):1643-5. PubMed ID: 11374718
    [No Abstract]   [Full Text] [Related]  

  • 12. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
    Kuhn RJ; Gelrud A; Munck A; Caras S
    Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study.
    Saito T; Hirano K; Isayama H; Nakai Y; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Hamada T; Takahara N; Uchino R; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
    Pancreas; 2017 Mar; 46(3):341-346. PubMed ID: 28099252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that predict the occurrence of and recovery from non-alcoholic fatty liver disease after pancreatoduodenectomy.
    Sato T; Matsuo Y; Shiga K; Morimoto M; Miyai H; Takeyama H
    Surgery; 2016 Aug; 160(2):318-30. PubMed ID: 27211602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
    Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
    Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system.
    Kato H; Isaji S; Azumi Y; Kishiwada M; Hamada T; Mizuno S; Usui M; Sakurai H; Tabata M
    J Hepatobiliary Pancreat Sci; 2010 May; 17(3):296-304. PubMed ID: 19809782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
    Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
    J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.
    Sander-Struckmeier S; Beckmann K; Janssen-van Solingen G; Pollack P
    Pancreas; 2013 Aug; 42(6):983-9. PubMed ID: 23587850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Kishi Y; Shimada K; Nara S; Esaki M; Kosuge T
    Pancreas; 2015 Aug; 44(6):983-7. PubMed ID: 25899648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancrelipase for pancreatic disorders: An update.
    Dhanasekaran R; Toskes PP
    Drugs Today (Barc); 2010 Nov; 46(11):855-66. PubMed ID: 21225024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.